Lionco Pharmaceutical Hits Day Low of CNY 5.32 Amid Price Pressure

Lionco Pharmaceutical Group Co., Ltd. experienced significant volatility on July 21, 2026, with the stock hitting an intraday low of CNY 5.32, reflecting a decline of 9.98% for the day. This performance starkly contrasts with the China Shanghai Composite, which gained 1.79% during the same period. Over the past week, Lionco's stock has seen a steep drop of 28.11%, while its one-year performance shows a decline of 14.61%. The company has struggled with long-term growth, evidenced by a net sales contraction of 18.44% annually over the last five years. Additionally, the operating profit has plummeted by 193.98%, indicating ongoing financial difficulties. Financial metrics reveal a low return on capital employed (ROCE) of 3.26%, suggesting inefficiencies in generating profits relative to capital. The company's debt-equity ratio stands at a high 12.69%, raising concerns about its financial leverage. With a market capitalization of CNY 2,899 million, Lionco remains a small-cap player in the pharmaceuticals and biotechnology sector, facing challenges in both short-term and long-term performance.